Endurance Wealth Management’s ADMA Biologics ADMA Stock Holding History

Endurance Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-300	Closed	-$3K	–	522
2015 Q3	$3K	Hold	300	–	–	﹤0.01%	467
2015 Q2	$3K	Buy	+300	New	+$2.6K	﹤0.01%	474

Other funds holding ADMA

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Endurance Wealth Management's ADMA Position: Q4 2015 in Review

Endurance Wealth Management sold out of ADMA Biologics (ADMA) in Q4 2015, closing a stake of 300 shares — an estimated $3K sold.

Endurance Wealth Management first reported a position in ADMA in Q2 2015 and held it in 2 quarters. The position peaked at $3K in Q3 2015. 26 funds tracked by Wall St. Rank hold ADMA as of Q4 2015.

Endurance Wealth Management reported no remaining ADMA Biologics position as of Q4 2015 after selling out during the quarter.
Endurance Wealth Management sold 300 ADMA Biologics shares in Q4 2015, an estimated $3K.
Endurance Wealth Management first reported a position in ADMA Biologics in Q2 2015 and held it in 2 quarters.
Endurance Wealth Management's ADMA Biologics position peaked at $3K in Q3 2015.
26 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2015.

Based on Endurance Wealth Management's 13F filing for Q4 2015, filed 27 Jan 2016.